Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Immatics N.V.NASDAQ: IMTX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 0.1 pp year over year. Over 3 fiscal years it widened by 61.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
100.0%+0.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+0.0 pp——
3 years+61.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How IMTX compares with its peers on the latest reported figures

  • IMTX's LTM Mar 2026 gross margin of 100.0% is the highest of the 10 companies compared; the peer median is 81.9%.
  • Its year-over-year change of +0.1 pp is the 4th highest of 10, against a peer median of -3.0 pp.
  • Over three fiscal years its change of +61.8 pp compares with a peer median of -5.1 pp.
IMTX Competitors Peer median
Gross Margin for IMTX and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 202696.1% +15.9 pp+407.1 pp
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding IMTX) 81.9%-3.0 pp-5.1 pp

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.